This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: diabetes mellitus

July 2025 Br J Cardiol 2025;32(3) doi:10.5837/bjc.2025.033 Online First

Auditing CV risk assessment of inpatients with acute high-risk chest pain: room for improvement?

Sasha T Gold, Muhammad H Riaz, Fraser C Goldie, Adrian J B Brady

Abstract

Introduction Low-density lipoprotein-cholesterol (LDL-C) is accepted as a causal risk factor for development of atherosclerotic cardiovascular disease (CVD) and acute coronary syndromes (ACS).1 European Society of Cardiology (ESC) guidelines have been extensive in setting up lipid targets for primary and secondary prevention of CVD.2 The 2021 ESC guidelines carry forward the 2019 ESC dyslipidaemia targets to introduce a therapeutic regimen that achieves a ≥50% LDL-C reduction from baseline and a LDL-C goal of <1.4 mmol/L (<55 mg/dL) (very-high-risk group) or <1.8 mmol/L (high-risk group).2 The updated National Institute for Health

| Full text

June 2025 Br J Cardiol 2025;32(2) doi:10.5837/bjc.2025.027 Online First

Acute myocardial infarction in a young patient with diabetes and ulcerative colitis

Chukwuemeka Lekwa, Jomith Jose, Saad Ahmad, Sunita Avinash

Abstract

Introduction Acute myocardial infarction (AMI) in young patients with systemic inflammatory diseases, such as ulcerative colitis and diabetes mellitus, presents a unique clinical challenge that deviates from traditional cardiovascular risk models. This case aims to highlight the complexities of managing AMI in the presence of systemic inflammation and metabolic disorders, emphasising the need for comprehensive care strategies and a multi-specialty approach for effective management in such cases. The report is relevant to current practice, as it stresses the importance of integrated and interdisciplinary care in managing cardiovascular risk in

| Full text
Prescribing glucose-lowering drugs for patients with cardiac disease

June 2018 Br J Cardiol 2018;25:73–6 doi:10.5837/bjc.2018.016

Prescribing glucose-lowering drugs for patients with cardiac disease

Miles Fisher, Emma Johns, Gerry McKay

Abstract

(more…)

| Full text
Older antidiabetic drugs

March 2018 doi:10.5837/bjc.2018.007

Older antidiabetic drugs

Emma Johns, Gerry McKay, Miles Fisher

Abstract

(more…)

| Full text
Glucagon-like peptide-1 (GLP-1) receptor agonists

November 2017 Br J Cardiol 2017;24:152–5 doi:10.5837/bjc.2017.030

Glucagon-like peptide-1 (GLP-1) receptor agonists

Emma Johns, Gerry McKay, Miles Fisher

Abstract

(more…)

| Full text
Glitazones (thiazolidinediones)

July 2017 Br J Cardiol 2017;24:113–16 doi:http://doi.org/10.5837/bjc.2017.018 Online First

Glitazones (thiazolidinediones)

Emma Johns, Gerry McKay, Miles Fisher

Abstract

(more…)

| Full text
SGLT2 inhibitors

April 2017 Br J Cardiol 2017;24:68-71 doi:10.5837/bjc.2017.010 Online First

SGLT2 inhibitors

Emma Johns, Gerry McKay, Miles Fisher

Abstract

(more…)

| Full text
Dipeptidyl peptidase-4 (DPP-4) inhibitors

January 2017 Br J Cardiol 2017;24:(1) doi:10.5837/bjc.2017.001 Online First

Dipeptidyl peptidase-4 (DPP-4) inhibitors

Emma Johns, Gerry McKay, Miles Fisher

Abstract

(more…)

| Full text

November 2007 Br J Cardiol 2007;14:267-71

The JBS 2 guidelines for the prevention of cardiovascular disease in people with diabetes: an approach to implementation

James D Lee, Sakera Shaikh, John R Morrissey, Vinod Patel

Abstract

The need for new guidelines The aim of the first guidelines from the Joint British Societies (JBS 1) was to promote a more effective multi-disciplinary approach to cardiovascular disease (CVD) prevention.4 The guidelines addressed the needs of both individuals with established disease and apparently healthy subjects at high risk of developing disease. The National Service Framework for Coronary Heart Disease (CHD) for England and Wales endorsed the lifestyle and risk factor targets in JBS 1.5 It also established national audit standards, which were subsequently reinforced and expanded by the General Medical Services contract for primary care.

| Full text

September 2004 Br J Cardiol 2004;11:379-86

Cocoa, flavanols and cardiovascular risk

Norman K Hollenberg, Harold Schmitz, Ian MacDonald, Neil Poulter

Abstract

No content available

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now